Literature DB >> 23719847

Prevalence and clinical characteristics of primary aldosteronism in Japanese patients with type 2 diabetes mellitus and hypertension.

Kunitaka Murase1, Ryoko Nagaishi, Hiromasa Takenoshita, Takashi Nomiyama, Yuko Akehi, Toshihiko Yanase.   

Abstract

The prevalence of primary aldosteronism (PA) is around 3-15% in patients with hypertension. Hypertension is a frequent complication of type 2 diabetes mellitus (DM) because of the close etiological relationship between these two diseases. However, the possibility of PA in patients with DM and hypertension is often overlooked and the prevalence of PA in patients with DM and hypertension in Japan is unknown. We enrolled 124 hospitalized patients with both DM and hypertension. PA was diagnosed according to the modified criteria for Japanese patients. We examined the prevalence of PA and compared clinical characteristics between patients with and without PA. In another analysis of 43 patients with a confirmed diagnosis of PA, we compared the characteristics of patients with and without DM. Overall, 14/124 patients with DM and hypertension (11.3%) were diagnosed with PA. Multivariate logistic regression showed that the duration of DM was significantly shorter in the PA group. Fisher's direct probability test revealed that history of hypertension before the diagnosis of DM was a significant factor in patients with PA. Treatment with an angiotensin II receptor blocker (ARB) did not affect the diagnosis of PA in these patients. Among 43 patients with PA, those with DM were significantly older and the delay to the diagnosis of PA was significantly longer compared with patients without DM. In conclusion, almost 10% of patients with DM and hypertension actually have PA. More extensive screening for PA is recommended in patients with DM and hypertension, regardless of the use of ARBs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23719847     DOI: 10.1507/endocrj.ej13-0060

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  5 in total

1.  Primary Aldosteronism With Type 2 Diabetes Mellitus Requires More Antihypertensive Drugs for Blood Pressure Control: A Retrospective Observational Study.

Authors:  Kennosuke Ohashi; Takeshi Hayashi; Yui Watanabe; Koichiro Hara; Rikako Ukichi; Hiroshi Asano; Hirofumi Suzuki; Kenji Yamashiro; Katsuyoshi Tojo; Masaya Sakamoto; Kazunori Utsunomiya
Journal:  J Clin Med Res       Date:  2017-12-01

2.  Surgical outcomes of patients with primary aldosteronism lateralized with I-131-6 β-iodomethyl-norcholesterol single photon emission/computed tomography without discontinuation or modification of antihypertensive medications.

Authors:  Chia-Hui Chang; Stephen Shei-Dei Yang; Yao-Chou Tsai; Shi-Wen Kuo; Shiou-Chi Cherng; Ching-Chu Lu; Ruoh-Fang Yen; Vin-Cent Wu; Ya-Hui Hu
Journal:  Ci Ji Yi Xue Za Zhi       Date:  2018 Jul-Sep

3.  Impact of primary aldosteronism on renal function in patients with type 2 diabetes.

Authors:  Sho Katsuragawa; Yuya Tsurutani; Tomoko Takiguchi; Jun Saito; Tetsuo Nishikawa
Journal:  J Diabetes Investig       Date:  2020-07-26       Impact factor: 4.232

4.  Higher Screening Aldosterone to Renin Ratio in Primary Aldosteronism Patients with Diabetes Mellitus.

Authors:  Chia-Hui Chang; Ya-Hui Hu; Kuo-How Huang; Yen-Hung Lin; Yao-Chou Tsai; Che-Hsiung Wu; Shao-Yu Yang; Chin-Chen Chang; Ching-Chu Lu; Kwan-Dun Wu; Vin-Cent Wu
Journal:  J Clin Med       Date:  2018-10-16       Impact factor: 4.241

5.  Higher Blood Urea Nitrogen and Urinary Calcium: New Risk Factors for Diabetes Mellitus in Primary Aldosteronism Patients.

Authors:  Yu Liu; Liang Zhou; Zhenghuan Liu; Yucheng Ma; Lede Lin; Yuchun Zhu; Kunjie Wang; Hong Li
Journal:  Front Endocrinol (Lausanne)       Date:  2020-02-04       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.